サンプル依頼リスト カート
  • English
  • Korean
表紙：マントル細胞リンパ腫の世界市場-2023年～2030年
市場調査レポート
商品コード
1345426

マントル細胞リンパ腫の世界市場-2023年～2030年

Global Mantle Cell Lymphoma Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
マントル細胞リンパ腫の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

マントル細胞リンパ腫の世界市場は2022年に21億米ドルに達し、2023-2030年の予測期間中にCAGR 6.1％で成長し、2030年には29億米ドルに達すると予測されています。

マントル細胞リンパ腫（MCL）は、B細胞性非ホジキンリンパ腫のひとつで、リンパ節内の腫瘍が血液に入り、骨髄、脾臓、消化管、肝臓に転移することで発症します。このタイプのがんは通常、徐々に増殖してから急速に増殖し始めます。マントル細胞リンパ腫はすぐにリンパ系全体に広がり、体の他の部分にも広がります。

マントル細胞リンパ腫の患者の約10人に1人は、進行の遅いタイプです。マントル細胞リンパ腫（MCL）は予後不良です。中悪性度の非ホジキンリンパ腫（NHL）に類似した中等度の侵攻性の経過を示します。中悪性度リンパ腫とは異なり、現在利用可能な標準治療で治癒することはほとんどないです。

さらに、標的治療薬の新興国市場の開拓、腫瘍学分野への支出の増加、薬剤開発戦略や発見の増加は、今後の市場を牽引するいくつかの要因です。

ダイナミクス

製品上市の増加

近年、新しい細胞タイプや技術が、現在の治療法や対象となる疾患の性質がもたらす課題を克服するために使用されるようになり、その結果、重篤な疾患の治療や治癒が可能になっています。リンパ腫は、B細胞、T細胞、および成熟段階の異なるリンパ球のサブセットのクローン性増殖から発生する悪性腫瘍の不均一なグループです。特定のリンパ腫のために発売された製品は、サブセットの治療に使用されます。

2023年3月、アストラゼネカの次世代選択的ブルトン型チロシンキナーゼ（BTK）阻害剤であるカルケンス（アカラブルチニブ）は、少なくとも1つの前治療を受けたマントル細胞リンパ腫（MCL）成人患者の治療薬として、中国で条件付き承認されました。これはカルケンスにとって中国で初めて承認された適応症です。

治験の増加

臨床腫瘍学の治験の登録件数は着実に増加しています。例えば、WHO国際治験登録プラットフォーム（ICTRP）のデータによると、2013年にはこの分野で約19,211件の治験が登録され、2022年にはその数は26,396件に増加しています。近年、免疫療法、精密医療、遺伝子治療、併用療法など、がん治験において数々の画期的な進歩が見られます。

Lymphoma Academic Research OrganisationとInstitute of Cancer Researchは共同で、新たにマントル細胞リンパ腫（MCL）と診断された患者（18歳以上80歳未満）を対象に、イブルチニブ/抗CD20 Abとイブルチニブ/抗CD20 Ab/ベネトクラックスを一定期間併用投与した場合の有効性を比較する第2相治験を実施しました。終了予定日は2031年9月30日です。

標的治療薬による副作用の発現

標的治療薬には、標準的または従来の化学療法とは異なる副作用があります。血管新生阻害薬は多くの場合、血管内皮増殖因子（VEGF）タンパク質を標的とします。ベバシズマブ（アバスチン）は、皮膚細胞が正常に成長するためのシグナルを遮断し、水分を保持しにくくします。手足症候群（HFS）は、いくつかの標的療法を含む多くのがん治療薬と関連しています。一部の標的治療薬、特に血管新生阻害薬は血圧を上昇させる可能性があります。米国がん協会によれば、特定の感染症やがんのリスクの増加も観察されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 製品上市の増加
      • 治験の増加
    • 抑制要因
      • 標的治療による副作用の発現
    • 機会
      • 腫瘍分野への投資の増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 診断別

  • 臨床検査
  • 画像検査
  • 骨髄生検
  • その他

第8章 薬物／治療法別

  • 診断
    • 画像検査
    • 外科的検査
    • その他
  • 薬物療法
    • 化学療法
      • アカラブルチニブ
      • イブルチニブ
      • ピルトブルチニブ
      • ザヌブルチニブ
      • その他
    • 標的療法
      • モノクローナル抗体療法
    • 免疫療法
      • CAR-T細胞療法
    • 幹細胞移植
    • その他

第9章 エンドユーザー別

  • 病院
  • クリニック
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Kite Pharma, Inc.（Gilead Sciences, Inc.）
    • 企業概要
    • 診断ポートフォリオと説明
    • 財務概要
    • 主な動向
  • F. Hoffman La Roche Ltd
  • Abbvie, Inc.
  • Celgene Corporation
  • Eli Lilly and Company
  • Amgen, Inc.
  • Takeda Pharmaceutical Co. Ltd
  • AstraZeneca Plc
  • Johnson and Johnson
  • BeiGene GmBH

第13章 付録

目次
Product Code: PH2172

Overview

Global Mantle Cell Lymphoma Market reached US$ 2.1 billion in 2022 and is expected to reach US$ 2.9 billion by 2030 growing with a CAGR of 6.1% during the forecast period 2023-2030.

Mantle cell lymphoma (MCL) is one of the B-cell non-Hodgkin lymphomas that occur due to tumors in the lymph nodes, which enter the blood and spread to the bone marrow, spleen, digestive tract, and liver. This type of cancer usually grows gradually before starting to grow more rapidly. Mantle cell lymphoma quickly spreads throughout your lymphatic system and to other body parts.

About 1 in 10 people with mantle cell lymphoma carry a slow-growing version of the condition. Mantle cell lymphoma (MCL) is associated with a poor prognosis. It exhibits a moderately aggressive course similar to intermediate-grade non-Hodgkin lymphoma (NHL). Unlike intermediate-grade lymphomas, it is rarely curable with currently available standard treatment.

Furthermore, the growing development of targeted therapy drugs, rising expenditure in the oncology sector, and increase in drug development strategies and discoveries are a few factors that drive the market in the forthcoming period.

Dynamics

Increasing Product Launches

In recent years, new cell types and technologies have been used to overcome challenges posed by current treatments and the nature of the targeted diseases, thus enabling us to treat and cure severe disorders. Lymphomas are a heterogeneous group of malignancies that arise from the clonal proliferation of B cell, T-cell, and subsets of lymphocytes at different stages of maturation. The products launched for a specific lymphoma are used for treating the subsets.

In March 2023, AstraZeneca's Calquence (acalabrutinib), a next-generation, selective Bruton's tyrosine kinase (BTK) inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This is the first approved indication for Calquence in China.

Rising Clinical Trials

The number of registered clinical oncology clinical trials has steadily increased. For instance, according to data from the WHO International Clinical Trials Registry Platform (ICTRP), in 2013, approximately 19,211 trials were registered in this field, and by 2022, that number had grown to 26,396. Recent years have witnessed numerous breakthroughs in oncology clinical trials, spanning immunotherapies, precision medicine, gene therapy, and combination therapy.

The Lymphoma Academic Research Organisation and Institute of Cancer Research collaborated to conduct phase 2 clinical trials to compare the efficacy of Ibrutinib/anti-CD20 Ab versus Ibrutinib/anti-CD20 Ab/Venetoclax given as fixed duration combinations in newly diagnosed Mantle Cell Lymphoma (MCL) patients (≥ 18 years and < 80 years of age). The estimated completion date is September 30, 2031.

Onset of Side Effects Due to Targeted Therapies

Targeted therapy drugs have different side effects than standard or traditional chemotherapy. Angiogenesis inhibitors often target vascular endothelial growth factor (VEGF) proteins. Bevacizumab (Avastin) turns off the signal for skin cells to grow normally, making it harder for them to retain moisture. Hand-foot syndrome (HFS) has been linked to many cancer treatment drugs, including some targeted therapies. Some targeted drugs, especially angiogenesis inhibitors, can raise blood pressure. Increased risks of certain infections and cancers are also observed, according to the American Cancer Society.

Segment Analysis

The global mantle cell lymphoma is segmented based on diagnosis, drug/therapy, end user, and region.

The Targeted Therapy Segment Accounted for Approximately 37.8% of the Market Share

Developing targeted agents with low toxicity profiles for treating relapsed mantle cell lymphoma (MCL) in combination with approved drugs is a major factor in augmenting the mantle cell lymphoma treatment market growth. The introduction of the novel targeted agent's ibrutinib (Imbruvica), acalabrutinib (Calquence), and venetoclax (Venclexta), among others, is rapidly changing the relapsed/refractory space of the mantle cell lymphoma (MCL) and the upfront setting of chronic lymphocytic leukemia (CLL), according to James N. Gerson, MD.

For instance, a Phase II study of bendamustine and rituximab plus venetoclax in untreated mantle cell lymphoma over 60 years of age by PrECOG, LLC. In collaboration with Genentech, Inc., expected to be completed by March 2025 and a Pilot Study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab for untreated mantle cell lymphoma by Washington University School of Medicine in collaboration with Acerta Pharma BV estimated to be completed by November 2025.

Geographical Analysis

North America accounted for Approximately 39.3% of the Market Share in 2022

Clinical trials are essential to improving cancer treatment, especially in highly lethal cancers like mantle cell lymphoma. Major cancer organizations, including the National Comprehensive Cancer Network, American Society of Clinical Oncology, and Association of Community Cancer Centers, endorse that all cancer patients should consider and have the opportunity to participate in clinical trials.

M.D. Anderson Cancer Center is conducting phase 2 clinical trials. This phase II trial studies the side effects of acalabrutinib and rituximab and its effect in treating patients with previously untreated mantle cell lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. Giving acalabrutinib and rituximab may help to control mantle cell lymphoma in elderly patients. The estimated completion date is August 30, 2026.

Furthermore, according to the rare disease organization, MCL usually occurs at 60 to 70 years old, and since the United States has a large pool of geriatric population is expected to dominate the global market.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global mantle cell lymphoma market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity. The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting drug development activities worldwide. The COVID-19 pandemic severely disrupted global supply chains, affecting the transportation of raw materials to pharmaceutical manufacturing industries.

The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. This diversion of resources and attention may have temporarily impacted the progress of cancer-related research and development activities. This has led to delays in the completion of trials and the availability of new therapies, which has affected the market. Furthermore, due to the socializing restrictions, regular healthcare checkups were difficult, leaving most patients with mantle cell lymphoma undetected, negatively impacting the global mantle cell lymphoma market growth during the pandemic.

By Diagnosis

  • Laboratory exams
  • Imaging Tests
  • Bone marrow Biopsy
  • Others

By Drug/Therapy

  • Chemotherapy
    • Acalabrutinib
    • ibrutinib
    • pirtobrutinib
    • zanubrutinib
    • Others
  • Targeted Therapy
    • Monoclonal Antibody Therapy
      • Immunotherapy
  • CAR T-cell therapy
    • Stem Cell Transplantation
    • Others

By End User

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In June 2023, Gilead Sciences, Inc. and Kite Pharma, a Gilead Company presented 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11.
  • In January 2023, Loxo Lilly, the oncology unit of Eli Lilly and Company, announced that the U.S. Food and Drug Administration (FDA) approved Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor.
  • On 16 August 2022, FDA accepted the supplemental Biologics License Application for Roche's Policy combination for people with previously untreated diffuse large B-cell lymphoma.

Competitive Landscape

The major global players in the mantle cell lymphoma market include: Kite Pharma, Inc. (Gilead Sciences, Inc.), F. Hoffman La Roche Ltd, Abbvie, Inc., Celgene Corporation, Eli Lilly and Company, Amgen, Inc., Takeda Pharmaceutical Co. Ltd, AstraZeneca Plc, Johnson and Johnson, and BeiGene GmBH among others.

Why Purchase the Report?

  • To visualize the global mantle cell lymphoma market segmentation based on diagnosis, drug/therapy, end user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of mantle cell lymphoma market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global mantle cell lymphoma market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Diagnosis
  • 3.2. Snippet by Drug/Therapy
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Product Launches
      • 4.1.1.2. Rising Clinical Trials
    • 4.1.2. Restraints
      • 4.1.2.1. Onset of Side Effects due to Targeted Therapies
    • 4.1.3. Opportunity
      • 4.1.3.1.1. Increasing Investments in Oncology Sector
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Diagnosis

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 7.1.2. Market Attractiveness Index, By Diagnosis
  • 7.2. Laboratory exams
  • 7.3. Imaging Tests
  • 7.4. Bone marrow Biopsy
  • 7.5. Others

8. By Drug/Therapy

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis
  • 8.2. Diagnosis
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 8.2.3. Imaging Tests
    • 8.2.4. Surgical Examination
    • 8.2.5. Others
  • 8.3. Drug/Therapy
    • 8.3.1. Chemotherapy
      • 8.3.1.1.1. Acalabrutinib
      • 8.3.1.1.2. ibrutinib
      • 8.3.1.1.3. pirtobrutinib
      • 8.3.1.1.4. zanubrutinib
      • 8.3.1.1.5. Others
    • 8.3.2. Targeted therapy
      • 8.3.2.1.1. Monoclonal Antibody Therapy
    • 8.3.3. Immunotherapy
      • 8.3.3.1.1. CAR T-cell therapy
    • 8.3.4. Stem Cell Transplantation
    • 8.3.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals
  • 9.3. Clinics
  • 9.4. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug/Therapy
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug/Therapy
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug/Therapy
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug/Therapy
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug/Therapy
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Kite Pharma, Inc. (Gilead Sciences, Inc.)
    • 12.1.1. Company Overview
    • 12.1.2. Diagnosis Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. F. Hoffman La Roche Ltd
  • 12.3. Abbvie, Inc.
  • 12.4. Celgene Corporation
  • 12.5. Eli Lilly and Company
  • 12.6. Amgen, Inc.
  • 12.7. Takeda Pharmaceutical Co. Ltd
  • 12.8. AstraZeneca Plc
  • 12.9. Johnson and Johnson
  • 12.10. BeiGene GmBH

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us